1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

        <em id="8sgz1"><label id="8sgz1"></label></em>
      2. <em id="8sgz1"><label id="8sgz1"></label></em>
        <em id="8sgz1"></em>
        <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

        <button id="8sgz1"></button>
        west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword "Thyroid carcinoma" 16 results
        • EXPERIENCE IN DIAGNOSIS AND TREATMENT FOR HASHIMOTO′S DISEASE (REPORT OF 78 CASE)

          Objective To sum up experiences in diagnosis and treatment for Hashimoto′s disease (HD). Methods Clinical records of 78 patients who underwent operations and were diagnosed as Hashimoto′s disease by histologic examination in our hospital from Jan. 1988 to Dec. 1998 were analyzed. Results Seventy females and 8 males, aged 9 to 70 years (average of 41.6 years). HD was coexistent with 10.3% of thyroid gland malignant tumor, 23.1% of adenoma and 30.8% of other thhroid gland diseases. The misdiagnosis rate was 35.9% and missed diagnosis rate was 46.2%. The clinical feature of HD and most common cause of misdiagnosis and missed diagnosis have been discussed. Conclusion It is emphasized that patients with diffuse goiter, palpable nodules, lighty color on scintillation scintigraphy, elevation of antimicosomiaux and antithyroglobuline but no finding on Bus should be highly suspected of having Hashimoto′s disease.

          Release date:2016-09-08 02:00 Export PDF Favorites Scan
        • THE CLINICAL FEATURE OF GRAVES’ DISEASE ASSOCIATED WITH THYROID CANCER

          From 1972 to 1992, 333 patients underwent operations because of Graves’ disease in our hospital. Histological examination of resected thyroid tissue revealed carcinoma in 8 cases, which accounted for 2.4%(8/333). With reviewing the literatures basing on a lot of literature, we lay emphasis on the clinical feature of the disease, cause of misdiagnosis, and the diagnosis and treatment of the disease are discussed.

          Release date:2016-08-29 03:19 Export PDF Favorites Scan
        • Research Progress of Electrical Impedance Spectrum Technology in The Diagnosis of Thyroid Carcinoma

          Objective To summarize the basic principle of electrical impedance spectrum technology and the latest progress in the diagnosis of thyroid carcinoma. Methods By the domestic and overseas literatures review, medical application and diagnostic prospect in thyroid carcinoma of electrical impedance spectrum were summarized. Results Electrical impedance spectrum was a kind of somatic function imaging, whose measurement results was objective, and it could diagnose thyroid carcinoma in early stage effectively. In addition, it could be used as a complementary form of fine needle aspiration biopsy, improving the diagnostic accuracy rate of thyroid carcinoma, thereby reducing the unessential thyroid operations. Conclusion Electrical impedance spectrum technology is a potentially useful imaging modality for diagnosing thyroid carcinoma in early stage, and functions as a auxiliary clinical diagnosis method for fine needle aspiration biopsy.

          Release date:2016-09-08 10:35 Export PDF Favorites Scan
        • Evidence-Based Diagnosis and Treatment for a Patient with Thyriod Carcinoma Showing Thymus-like Differentiation

          Objective To discuss the diagnosis, treatment, and follow-up visit mode of thyroid carcinoma showing thymus-like elements (CASTLE). Mothods For a systematic review of a case with CASTLE, the domestic and overseas literature was searched to analyze final diagnosis, treatment and follow-up visit indexes of that case. Results For CASTLE, the pathology combined with immunohistochemistry was the only method for final diagnosis, the operation was the main treatment, and the ultrasound as well as the computed tomography (CT) could be the follow-up visiting indexes. Conclusion CASTLE is a special kind of thyroid carcinoma, which is different from differentiated thyroid carcinoma in diagnosis, treatment and follow-up visit.

          Release date:2016-09-07 11:03 Export PDF Favorites Scan
        • Research Advance of Relationship Between RET Proto-Oncogene and Differentiated Thyroid Carcinoma

          Objective To review recent studies on the research advance of the relationship between RET proto-oncogene and differentiated thyroid carcinoma. Methods The literatures in recent years on the structure of RET gene and coding product,cell signal transduction,relationship between RET proto-oncogene and differentiated thyroid carcinoma were reviewed. Results RET gene encoding tyrosine kinase receptor,involving in cell signal transduction,rearrangement of RET gene was frequently seen in papillary thyroid carcinoma. Conclusion Rearrangement of RET gene was closely correlated with the occurrence and progress of differentiated thyroid carcinoma,RET gene may be considered as a new therapeutic target for differentiated thyroid carcinoma.

          Release date:2016-08-28 04:43 Export PDF Favorites Scan
        • Clinical Analysis of Primary Hyperthyroidism Complicated with Thyroid Carcinoma (Report of 15 Cases)

          Objective To analyze the clinical relationship between primary hyperthyroidism and thyroid carcinoma, and diagnosis and treatment for the combination of the two. Methods The clinical data of 15 patients with primary hyperthyroidism complicated with thyroid carcinoma from January 1998 to December 2008 were retrospectively analyzed. Results Fifteen cases were smoothly discharged. The morbidity was 2.56% (15/585) of primary hyperthyroidism complicated with thyroid carcinoma. There were no operative complications. Five cases showed thyroid nodules and all cases were performed thyroidectomy. Neither hyperthyroidism nor thyroid carcinoma recurred during 9 months to 10 years (average 5.5 years) follow-up.Conclusions The diagnosis of primary hyperthyroidism complicated with thyroid carcinoma is still difficult to be made preoperatively and chiefly depend on postoperative pathology. Rational surgical treatment can result in good effectiveness and better prognosis.

          Release date:2016-09-08 04:26 Export PDF Favorites Scan
        • Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Thyroid Carcinoma Tissue and Their Concentrations in Serum

          Objective To explore the protein expressions of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1), and to investigate their relationships between their serum concentration before operation and the infiltration and metastasis of thyroid carcinoma. Methods The protein expressions of MMP-9 and TIMP-1 in 32 cases of thyroid carcinomas, 23 cases of adjacent tissues and 30 cases of benign hyperplastic lesions were measured by using immunohistochemistry. The preoperative serum concentrations of MMP-9 and TIMP-1 in 21 cases of thyroid carcinomas and 19 cases of benign hyperplastic lesions were determined by enzyme-linked immunosorbent assay. Results The positive expression rates of MMP-9 and TIMP-1 in tumor tissues were significantly higher (75.0%,56.3%)than those in adjacent tissues and benign hyperplastic lesions (30.4%, 21.7%; 26.7%, 23.3%)  P<0.05. There were correlations between the expressions of MMP-9 and TIMP-1 and the local infiltrative degrees, lymph node metastasis and TNM stage (P<0.05). There was a negative correlation between the expression of MMP-9 and the expression of TIMP-1 (r=-0.509, P=0.003). The concentration of MMP-9 in serum of thyroid carcinoma patients was (122.60±36.20) ng/ml, whereas TIMP-1 was (59.44±38.65)  ng/ml, both of which were significantly higher compared to those of benign group (P<0.05).  In addition, there was a positive correlation between the expressions of MMP-9/TIMP-1 in the carcinoma tissues and their concentrations in serum (P<0.05).Conclusion To detection the expressions of MMP-9 and TIMP-1 in the lesion and their concentrations in the serum may not only contribute to the differential diagnosis of thyroid tumors, but may also help to predict the prognosis of the carcinoma.

          Release date:2016-09-08 11:49 Export PDF Favorites Scan
        • The method of establishing a priority-scoring model for thyroid carcinoma surgery admission

          ObjectiveTo explore a method for establishing a priority-scoring model for thyroid carcinoma patient admission. MethodsA questionnaire survey was conducted among specialists and outpatients in the thyroid surgery department of the hospital. The weight coefficient of the index factors was calculated to establish the priority-scoring mode by the analytic hierarchy process. The differences in results between specialists and patients were compared. The logical rationality of the model index was tested. ResultsA priority-scoring model for thyroid carcinoma surgery admission was established, including 10 first-level indicators, such as sex, age, cancer type and TNM stage. The weight coefficients of the indicators from high to low were cancer type (0.137), TNM stage (0.134), tumor size (0.127), tumor invasion degree (0.126), tumor invasion site (0.124), relationship between tumor and capsule (0.111), age (0.093), sex (0.061), place of residence (0.05) and medical insurance type (0.035). After the total ratio test, the model CR value was 0.0073, and the model index was highly rational. ConclusionThis study successfully establish a priority-scoring model for thyroid carcinoma surgery admission, which can provide references and a basis for tiered medical services and relevant researches in the future.

          Release date:2022-07-14 01:12 Export PDF Favorites Scan
        • Investigation of Value ofNa+/I- Symporter Expression on Diagnosis of Thyroid Carcinoma and Prediction of 131I Therapeutic Effects

          Objective To study the clinical value ofNa+/I- symporter (NIS) expression on thyroid carcinoma diagnosis and 131I therapeutic effects prediction. Methods Thirty-one cases of thyroid carcinomas enrolled in this hospital from 1998 to 2006 were included. Using immunohistochemical method, NIS expression location, positive cell staining and expression intensity were observed, which was calculated by immunohistochemical scores (IHS) and NIS expression level was compared between primary and metastatic carcinoma. Results NIS was over-expressed on the basolateral membrane in positive control——Grave disease tissue, and showed no staining in negative control. NIS was expressed in cytoplasm in all 31 primary carcinomas, and IHS was over or equaled to 4 in 80.65% of them. Except for 2 no staining, NIS was expressed in cytoplasm in the rest 28 metastatic carcinomas. NIS expression was related to the pathological type of thyroid carcinoma, the best in PTC, then FTC, and the weakest in fvPTC. NIS expression in metastatic carcinoma was related to that in primary carcinoma.Conclusion NIS is over-expressed in cytoplasm in most thyroid carcinoma, and the iodide uptaking defect is mainly due to its wrong location. It has great potential to be applied in clinic by that it can help with the differential diagnosis of benign and malignant thyroid diseases, especially between FTA and FTC, and that it can help predict the therapeutic effects of 131I therapy following thyroid operation.

          Release date:2016-09-08 11:49 Export PDF Favorites Scan
        • Selection of Thyrotropin Suppression Therapeutic Timing in Postoperative Patients with Differentiated Thyroid Carcinoma

          ObjectiveTo observe changing trend of thyroid hormones levels for postoperative patients with differentiated thyroid carcinoma,and to discuss the best therapeutic timing of thyrotropin (TSH) suppression. MethodsNinety-six patients with differentiated thyroid carcinoma from January 2011 to December 2013 in this hospital were selected.All of these 96 cases were divided into total thyroidectomy group (n=50) and thyroid lobectomy and isthmectomy group (n=46) according to the surgical approach.Serum thyroid hormones levels (T3,FT3,T4,FT4,and TSH) were detected on day 1,2,4,5,7,14 after operation. Results① In the total thyroidectomy group,the levels of T3 and FT3 elevated transiently on day 5,then decreased gradually,and which were lower than the low limit of normal range on day 14.The levels of T4 and FT4 elevated transiently,then reached the peak on day 2,and which started to decrease gradually and reached the low limit of normal range on day 14.The value of serum TSH decreased transiently,which started to increase rapidly on day 2 and surpassed the high limit of normal range on day 4,then continued to rise until on day 14.② In the lobectomy and isthmectomy group,the values of T3 and FT3 decreased gradually,then started to rise on day 5,and which were lower than preoperative values until on day 14.The values of T4 and FT4 elevated transiently and which reached the peak on day 2,and then gradually decreased,which appeared to be lower than preoperative values on day 14.The value of TSH decreased transiently,and which started to rise on day 4,then elevated gradually and exceeded preoperative level on day 7,which reached the high limit of normal range on day 14. ConclusionsThere are dynamic changes of thyroid hormones in postoperative patients with differentiated thyroid carcinoma.It is feasible to determine the best therapeutic timing of TSH suppression according to the levels of postoperative thyroid hormones.The best timing of thyrotropin suppression therapy is that TSH is above the high limit of normal range after operation.

          Release date: Export PDF Favorites Scan
        2 pages Previous 1 2 Next

        Format

        Content

          1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

            <em id="8sgz1"><label id="8sgz1"></label></em>
          2. <em id="8sgz1"><label id="8sgz1"></label></em>
            <em id="8sgz1"></em>
            <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

            <button id="8sgz1"></button>
            欧美人与性动交α欧美精品